Skip to content 
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California. more
| Dec '23 | Dec '24 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 118.46M | 181.10M | [{"date":"2023-12-31","value":65.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |||
| Operating Income | (118.46M) | (181.10M) | [{"date":"2023-12-31","value":-11846100000,"profit":false},{"date":"2024-12-31","value":-18110100000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 24.62M | 34.78M | [{"date":"2023-12-31","value":70.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |||
| Pre-Tax Income | (106.15M) | (163.71M) | [{"date":"2023-12-31","value":-10615000000,"profit":false},{"date":"2024-12-31","value":-16370500000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (106.15M) | (163.71M) | [{"date":"2023-12-31","value":-10615000000,"profit":false},{"date":"2024-12-31","value":-16370500000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Net Income | (106.15M) | (163.71M) | [{"date":"2023-12-31","value":-10615000000,"profit":false},{"date":"2024-12-31","value":-16370500000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
| TRAX | |
|---|---|
| Current Ratio | 8.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| TRAX | |
|---|---|
| ROA (LTM) | -28.97% |
| ROE (LTM) | -48.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| TRAX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| TRAX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 2.32 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
First Tracks Biotherapeutics (TRAX) share price today is $17.055
Yes, Indians can buy shares of First Tracks Biotherapeutics (TRAX) on Vested. To buy
Yes, you can purchase fractional shares of First Tracks Biotherapeutics (TRAX) via the Vested app. You can start investing in First Tracks Biotherapeutics (TRAX) with a minimum investment of $1.
You can invest in shares of First Tracks Biotherapeutics (TRAX) via Vested in three simple steps:
The 52-week high price of First Tracks Biotherapeutics (TRAX) is $26.8. The 52-week low price of First Tracks Biotherapeutics (TRAX) is $11.3.
The price-to-earnings (P/E) ratio of First Tracks Biotherapeutics (TRAX) is
The price-to-book (P/B) ratio of First Tracks Biotherapeutics (TRAX) is 2.32
The dividend yield of First Tracks Biotherapeutics (TRAX) is 0.00%
The market capitalization of First Tracks Biotherapeutics (TRAX) is $599.45M
The stock symbol (or ticker) of First Tracks Biotherapeutics is TRAX
Consider the share price of First Tracks Biotherapeutics as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether First Tracks Biotherapeutics has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in First Tracks Biotherapeutics shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the First Tracks Biotherapeutics stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of First Tracks Biotherapeutics and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that First Tracks Biotherapeutics stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
